You are here

Some bladder cancer patients benefit from Roche therapy

BT_20160607_ROCHE_2320915.jpg
Results of the mid-stage trial could help make the case that Roche's drug should become the first option therapy of choice for patients with metastatic bladder cancer, says a researcher leading the study.

Chicago

A NEWLY approved immunotherapy from Roche Holding proved effective as an initial treatment for some patients with advanced bladder cancer, according to data presented on Sunday.

Results of the mid-stage trial could help make the case that the drug, Tecentriq, should become

sentifi.com

Market voices on:

grab

Receive $80 Grab vouchers valid for use on all Grab services except GrabHitch and GrabShuttle when you subscribe to BT All-Digital at only $0.99*/month.

Find out more at btsub.sg/promo

Powered by GET.comGetCom